An indirect comparison suggests that zanubrutinib confers a significant survival advantage in CLL compared with acalabrutinib plus venetoclax.
The post New Research Compares Survival Benefits of BTKi Regimens for Low-Risk CLL first appeared on Physician’s Weekly.
